Raise closed, search for fresh raises on Seedstage

Brooklyn, NY

Developing wearable brain stimulation technology for mental health treatment.

• Wearable Brain Stimulation: Fisher Wallace has developed a scalable form of wearable brain stimulation to treat mental health conditions.
• Regulatory Pathway: The company is seeking FDA approval for its Version 2.0 technology, known as OAK.
• Pilot Program: OAK is currently being tested at the US Department of Veterans Affairs.
• Business Model: Includes government procurement and reimbursement through insurance, as well as direct-to-patient channels.
• Clinical Validation: The technology has been validated in multiple studies and designed by teams behind popular consumer products.

Fisher Wallace is advancing its Version 2.0 technology, known as OAK, which is a wearable brain stimulation device aimed at treating anxiety, depression, and insomnia. The company is channeling its fundraising efforts towards FDA submission fees, a pilot program at the US Department of Veterans Affairs, and enhancing its manufacturing process and operations. The OAK device is designed for smartphone scale and is currently undergoing testing at the US Department of Veterans Affairs. The company has ceased marketing its Version 1.0 technology and is focused on obtaining regulatory approval for its new device.

Fisher Wallace’s technology has been validated in multiple studies and is designed by teams behind well-known consumer products. The company aims to address the inadequacies of current drug and behavioral therapies by offering a safe, self-administered, and rapidly effective alternative. The business model includes government procurement and reimbursement through commercial insurance, Medicaid, and Medicare. Fisher Wallace is also exploring direct-to-patient channels through eCommerce and telemedicine partnerships. The company has invested significantly in clinical research and product development to differentiate its product and achieve widespread adoption.

Company Info

Fisher Wallace develops wearable brain stimulation devices to treat mental health disorders, focusing on scalable, self-administered solutions.

Fisher Wallace develops and manufactures wearable transcranial alternating current stimulation (tACS) technology, also known as Cranial Electrotherapy Stimulation (CES), for treating neuropsychiatric and cognitive disorders. The company focuses on its Version 2.0 technology, branded as OAK, which aims to provide a safe, self-administered, and effective treatment for conditions such as anxiety, depression, and insomnia. This technology is designed for ease of use and is intended to be prescribed via telemedicine, allowing patients to receive treatment at home.

Fisher Wallace’s OAK device is currently undergoing testing and is on track for regulatory approval in early 2026. The company has collaborated with design teams from Beats and Nest to ensure a user-friendly experience. Fisher Wallace aims to address the needs of large patient populations, including veterans and younger generations, who require rapid-acting mental health solutions. The business model includes government procurement and partnerships with telehealth platforms to distribute their technology.